Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib, Paclitaxel, and Carboplatin in Metastatic Melanoma
NCT00288041Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2005
- Primary completion
- Sep 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in melanoma, sponsored by National Cancer Institute. Primary endpoints: Confirmed tumor response rate at 3 years and Adverse event profile at 3 years. Started Oct 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00288041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00288041.